In September last year, we reported Servier had advanced its emerging neurology pipeline into the clinical trials stage by ...
Drug Farm today announced that preliminary immunologic and clinical results from its Phase 1b study of DF-003, a ...
Mistletoe therapy may improve the QOL of patients with cancer; however, evidence does not support a survival benefit, ...
Dawe, PhD, as Scientific Advisor, Neuropharmacology & Translational Neuroscience, and Tomi K. Sawyer, PhD, as Strategic ...
MicroCloud Hologram Inc. (NASDAQ: HOLO), ("HOLO" or the "Company"), a technology service provider, developed a technology based on quantum key distribution protocol and quantum random number ...
Anxiety doesn't always get worse with age, but many people notice it feels more intense in their 50s, even if they've never ...
Dyve Biosciences, in collaboration with Moffitt Cancer Center, today reported significant study results for a first-of-its-kind investigational therapy applied to the skin and des ...
The East Asian Subtropical Westerly Jet (EASWJ) and the East Asian Summer Monsoon (EASM) are two pivotal components of the ...
A new report published this week outlines further details of Apple’s plan to combat the crease. According to TrendForce, two ...
Rising carbon dioxide (CO2) emissions from human activities are the largest contributor to global warming. According to the ...
The MarketWatch News Department was not involved in the creation of this content.-- FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary en ...
HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced the preclinical poster presentation titled, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results